|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson_Services,_Inc.
gptkb:Opsumit
gptkb:Tracleer
gptkb:Uptravi
|
|
gptkbp:acquired
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:ceo
|
gptkb:Martine_Clozel
|
|
gptkbp:employees
|
approximately 2,000
|
|
gptkbp:founded
|
gptkb:1997
|
|
gptkbp:founder
|
gptkb:Jean-Paul_Clozel
|
|
gptkbp:headquarters
|
gptkb:Allschwil,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Actelion Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:key_people
|
gptkb:David_E._Stump
gptkb:Peter_M._H._Huber
gptkb:Jean-Paul_Clozel
gptkb:Martine_Clozel
Thomas H. H. Huber
Jörg M. H. Huber
Michele A. H. Huber
Rainer M. H. Huber
Ralph M. H. Huber
Thomas M. H. Huber
Ursula M. H. Huber
|
|
gptkbp:products
|
gptkb:Selexipag
gptkb:Opsumit
gptkb:Tracleer
gptkb:Uptravi
|
|
gptkbp:revenue
|
$2.1 billion (2016)
|
|
gptkbp:specializes_in
|
pulmonary arterial hypertension
|
|
gptkbp:stock_exchange
|
gptkb:Swiss_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Actelion_Pharmaceuticals_Ltd.
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.actelion.com
|